Association of Beta Blocker Use with Exercise Capacity in Participants with Heart Failure with Preserved Ejection Fraction: A Post-Hoc Analysis of the RELAX Trial

Lajjaben Patel,Matthew W Segar,Neil Keshvani,Vinayak Subramanian,Ambarish Pandey,Alvin Chandra

DOI: https://doi.org/10.1016/j.amjcard.2024.01.023

IF: 3.133

2024-02-09

The American Journal of Cardiology

Abstract:Patients with heart failure with preserved ejection fraction (HFpEF) often receive beta-blocker (BB) therapy for management of co-morbidities. However, the association of BB therapy with exercise capacity and health related quality-of-life (HRQL) in HFpEF is not well-studied. In this post-hoc analysis of the RELAX trial, which included chronic stable patients with HFpEF with peak exercise capacity assessment at baseline, 12 weeks, and 24 weeks follow-up, we evaluated the association of BB use with measures of exercise capacity (peak exercise oxygen uptake, VO 2peak ), anaerobic threshold (VO 2 AT), and HRQL (Minnesota Living with Heart Failure Questionnaire, MLHFQ). Separate linear mixed-effect models were constructed for each outcome with adjustment for treatment arm, demographics, medical history, LVEF, and duration of HF. Of 216 study participants (median age: 69 years, 48.2% female), 76% reported baseline BB use. Participants with (vs. without) BB therapy were older (69.8 vs. 64.4 years, p=0.001) and had a higher prevalence of ischemic heart disease (44% vs. 23%, p=0.01). In adjusted linear mixed model, BB use over time was not associated with VO 2peak [β(95%CI): 0.2(-0.31, 0.7); p=0.45] and 6MWD [β (95%CI): 14.73(-14.21, 43.67); p=0.32]. However, BB use was associated with a higher VO 2 AT [β (95%CI): 0.32(0.02, 0.62), p=0.036] and better HRQL (lower MLWHF score) [β (95%CI): -6.68(-10.96, -2.4); p=0.002]. Future trials are needed to better evaluate the effects of BB on exercise capacity in patients with chronic stable HFpEF.

cardiac & cardiovascular systems